June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Therapeutic Effects of Topical RCI001 on Environmental and Inflammation-related Dry eye mouse Models
Author Affiliations & Notes
  • Dong Hyun Kim
    RudaCure Co., Ltd, Incheon, Korea (the Republic of)
    Ophthalmology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea (the Republic of)
  • Youngho Jung
    Ophthalmology, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  • Ja Yoon Moon
    Ophthalmology, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  • Seunghoon Kim
    RudaCure Co., Ltd, Incheon, Korea (the Republic of)
  • Young Ah Ku
    RudaCure Co., Ltd, Incheon, Korea (the Republic of)
  • Hawon Jeon
    RudaCure Co., Ltd, Incheon, Korea (the Republic of)
  • Ye Won Jang
    RudaCure Co., Ltd, Incheon, Korea (the Republic of)
  • Kyung Hwa Lee
    Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul, Korea (the Republic of)
  • JinSuk Ryu
    Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul, Korea (the Republic of)
  • Changho Yoon
    Ophthalmology, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
    Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul, Korea (the Republic of)
  • Mee Kum Kim
    Ophthalmology, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
    Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Dong Hyun Kim, Rudacure (P), Rudacure (I); Youngho Jung, None; Ja Yoon Moon, None; Seunghoon Kim, Rudacure (I); Young Ah Ku, Rudacure (E); Hawon Jeon, Rudacure (E); Ye Won Jang, Rudacure (E); Kyung Hwa Lee, None; JinSuk Ryu, None; Changho Yoon, None; Mee Kum Kim, None
  • Footnotes
    Support  This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (Grant number: NRF-2020R1C1C1007372).
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1322. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dong Hyun Kim, Youngho Jung, Ja Yoon Moon, Seunghoon Kim, Young Ah Ku, Hawon Jeon, Ye Won Jang, Kyung Hwa Lee, JinSuk Ryu, Changho Yoon, Mee Kum Kim; Therapeutic Effects of Topical RCI001 on Environmental and Inflammation-related Dry eye mouse Models. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1322.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the therapeutic effects of topical RCI001 on mouse models of environmental and inflammation-mediated dry eye disease (DED).

Methods : We used a scopolamine-induced environmental dry eye model in a dry chamber with 8-week-old BALB/c mice and 12-week-old NOD.B10.H2b mice, a model for primary Sjogren syndrome. The eyes of mice were topically treated with RCI001 and phosphate-buffered saline (PBS) twice a day for a week. Clinical findings such as ocular surface staining and tear production were assessed. Conjunctival goblet cell densities and inflammatory cytokines in the ocular surface and lacrimal gland were also analyzed.

Results : Topical application of RCI001 eyedrops resulted in a significant improvement of ocular surface staining and tear secretion in two mouse models, compared to the PBS-treated group. Although conjunctival goblet cell densities were not different between RCI001-treated and PBS-treated group, the expression of proinflammatory cytokines in the ocular surface and lacrimal gland of NOD.B10.H2b mice were repressed by RCI001, compared to PBS.

Conclusions : Topical RCI001 application showed significant therapeutic effects in two DED models via stimulating tear secretion and modulating inflammation.

This is a 2021 ARVO Annual Meeting abstract.

 

Therapeutic effects of RCI001 in Environmental DED model

Therapeutic effects of RCI001 in Environmental DED model

 

Therapeutic effects of RCI001 in Primary Sjogren syndrome model

Therapeutic effects of RCI001 in Primary Sjogren syndrome model

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×